SM
CERO

Selkirk Management’s CERo Therapeutics CERO Stock Holding History

Selkirk Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-61
Closed -$7.26K – 16
2024
Q4 		$7.26K Hold
61
– – ﹤0.01% 16
2024
Q3 		$11.3K Buy
+61
New +$18.6K ﹤0.01% 17

Other funds holding CERO

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Selkirk Management's CERO Position: Q1 2025 in Review

Selkirk Management sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 61 shares — an estimated $7.26K sold.

Selkirk Management first reported a position in CERO in Q3 2024 and held it in 2 quarters. The position peaked at $11.3K in Q3 2024. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • Selkirk Management reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Selkirk Management sold 61 CERo Therapeutics shares in Q1 2025, an estimated $7.26K.
  • Selkirk Management first reported a position in CERo Therapeutics in Q3 2024 and held it in 2 quarters.
  • Selkirk Management's CERo Therapeutics position peaked at $11.3K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Selkirk Management's 13F filing for Q1 2025, filed 15 May 2025.